Luxeptinib - Aptose Biosciences/CrystalGenomics
Alternative Names: CG-026806; CG-806Latest Information Update: 06 Jun 2024
At a glance
- Originator CrystalGenomics
- Developer Aptose Biosciences; CrystalGenomics
- Class Antineoplastics; Fluorobenzenes; Imidazoles; Isoindoles; Phenylurea compounds; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Apoptosis stimulants; Aurora kinase inhibitors; Discoidin domain receptor 2 antagonists; Extracellular signal-regulated MAP kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Interleukin 6 inhibitors; Lyn protein-tyrosine kinase inhibitors; NLRP3 protein inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-akt inhibitors; Proto-oncogene protein c-ret inhibitors; Src-family kinase inhibitors; Syk kinase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
- Preclinical Haematological malignancies; Mantle-cell lymphoma
Most Recent Events
- 06 Jun 2024 Luxeptinib is still in phase-I development in Chronic-lymphocytic-leukaemia (Second-line therapy or greater), Acute myeloid leukaemia (Second-line therapy or greater), Myelodysplastic syndromes, Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (PO, Capsule)
- 06 Jun 2024 Luxeptinib is still in preclinal development in Haematological malignancies in South Korea (PO, Capsule)
- 06 Jun 2024 Luxeptinib is still in preclinical development in Mantle cell lymphoma in Canada (Unspecified)